Abel Hall LLC
KYMR icon

Abel Hall LLC’s Kymera Therapeutics KYMR Stock Holding History

Abel Hall LLC’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$544K Buy
4,870
+189
+4% +$21.7K 0.1% 194
2026
Q2 		$537K Sell
4,681
-152
-3% -$13.1K 0.09% 218
2026
Q1 		$403K Sell
4,833
-1,003
-17% -$79.4K 0.09% 274
2025
Q4 		$454K Buy
+5,836
New +$394K 0.11% 197

Other funds holding KYMR

Harbor Capital Advisors
Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
KMWM
Keudell/Morrison Wealth Management Salem, Oregon $562M AUM 21.01% 1-Year Est. Return
Inspire Investing
Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
MASECO Private Wealth
MASECO Private Wealth London $3.65B AUM 9.71% 1-Year Est. Return
NorthCrest Asset Manangement
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
DMC Group
DMC Group Birmingham, Alabama $143M AUM 35.68% 1-Year Est. Return

Abel Hall LLC's KYMR Position: Q3 2026 in Review

Abel Hall LLC increased its Kymera Therapeutics (KYMR) stake by 4% in Q3 2026, buying an estimated $21.7K and bringing the position to 4,870 shares worth $544K. The position accounts for 0.1% of the portfolio, ranked #194.

Abel Hall LLC first reported a position in KYMR in Q4 2025 and has held it in 4 quarters since. 35 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • Abel Hall LLC held 4,870 shares of Kymera Therapeutics worth $544K as of Q3 2026.
  • Abel Hall LLC bought 189 Kymera Therapeutics shares in Q3 2026, an estimated $21.7K.
  • Kymera Therapeutics made up 0.1% of Abel Hall LLC's portfolio in Q3 2026, its #194 holding.
  • Abel Hall LLC first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 35 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.